EUVIMEDEUVIMED entdecken
Crossref

Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women

Jhohann Richard de Lima Benzi, Adriana Rocha, Julia Cristina Colombari, Alef Machado Gomes Pego, Patrícia Pereira Dos Santos Melli, Geraldo Duarte, Vera Lucia Lanchote

Journal of Pharmaceutical and Biomedical Analysis · 2023

DOI: 10.1016/j.jpba.2023.115635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2023. Verfasst von Jhohann Richard de Lima Benzi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão …. Hauptthemen laut MEDLINE: Furosemide, Glucuronides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Furosemide (FUR) has been used in probe drugs cocktails for in vivo evaluation of the renal transporters OAT1 and OAT3 activities in studies of drug-drug interactions (generally using probenecid as an inhibitor) and drug-disease interactions. The objective of this study was to develop and validate methods for FUR and its glucuronide metabolite (FUR-GLU) analysis in plasma, plasma ultrafiltrate and urine for application in pharmacokinetics studies: a pilot drug-drug interaction study in pregnant women (n = 2), who received a single oral dose of FUR (40 mg) and in another occasion a single oral dose of probenecid (750 mg) before a single oral dose of FUR (40 mg), and in non-pregnant women participants (n = 12), who only received a single oral dose of FUR (40 mg). The samples preparation for FUR in 50 µL of plasma and plasma lysate were carried by acidified liquid-liquid extraction, while 50 µL of urine and 200 µL of plasma ultrafiltrate were simply diluted with the mobile phase. The methods presented linearities in the range of 0.50 - 2500 ng/mL of plasma and plasma lysate, 0.125 - 250 ng/mL of plasma ultrafiltrate, and 50 - 20,000 ng/mL of urine. FUR-GLU methods presented linearities in the range of 0.125 - 250 ng/mL of plasma ultrafiltrate and 50 - 20,000 ng/mL of urine. Precision and accuracy evaluations showed coefficients of variation and relative errors < 15%. In the pregnant women participants, the mean values of FUR CLrenal, CLsecretion, CLformation. FUR-GLU and CLnon-renal were all reduced when probenecid was administered with FUR (8.24 vs 2.89 L/h, 8.15 vs 2.80 L/h, 3.86 vs 1.75 L/h, 48.26 vs 22.10 L/h, respectively). Non-pregnant women presented similar values of FUR CLrenal, CLsecretion, CLformation. FUR-GLU to the pregnant women who received FUR only. Finally, FUR fraction unbound (fu) resulted in values of approximately 1% in pregnant women and to 0.22% in non-pregnant women. These developed and validated methods for FUR and FUR-GLU quantification in multiple matrices can allow the further investigation of UGT1A9/1A1 and the fu when FUR is administered as an OAT 1 and 3 in vivo probe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FurosemideGlucuronidesFemaleHumansChromatography, High Pressure LiquidProbenecidTandem Mass Spectrometry

Stichwörter der Autor:innen

Fraction unboundFurosemideFurosemide glucuronideLC-MS/MSPregnancy

Substanzen

FurosemideGlucuronidesProbenecid

Autor:innen und Institutionen

  • Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Department of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
  • Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: lanchote@fcfrp.usp.br.

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Benzi, J. R. L., Rocha, A., Colombari, J. C., Pego, A. M. G., Dos Santos Melli, P. P., Duarte, G., & Lanchote, V. L. (2023). Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2023.115635

Vancouver

Benzi JRL, Rocha A, Colombari JC, Pego AMG, Dos Santos Melli PP, Duarte G, et al. Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women. Journal of Pharmaceutical and Biomedical Analysis. 2023. doi:10.1016/j.jpba.2023.115635

BibTeX
@article{Benzi2023,
  author = {Benzi, Jhohann Richard de Lima and Rocha, Adriana and Colombari, Julia Cristina and Pego, Alef Machado Gomes and Dos Santos Melli, Patrícia Pereira and Duarte, Geraldo and Lanchote, Vera Lucia},
  title = {Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women},
  journal = {Journal of Pharmaceutical and Biomedical Analysis},
  year = {2023},
  doi = {10.1016/j.jpba.2023.115635}
}
Kostenlos starten →